Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts

Antisense-mediated exon skipping has made significant progress as a therapeutic platform in recent years, especially in the case of Duchenne muscular dystrophy (DMD). Despite FDA approval of eteplirsen–the first-ever antisense drug clinically marketed for DMD–exon skipping therapy still faces the si...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Lee, Joshua, Echigoya, Yusuke, Duddy, William, Saito, Takashi, Aoki, Yoshitsugu, Takeda, Shin’ichi, Yokota, Toshifumi
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5957359/
https://ncbi.nlm.nih.gov/pubmed/29771942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0197084
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky